Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast 500 µg once daily vs placebo in type 2 diabetes mellitus
2005-005702-23Phase 2Completed
- Sponsor
- Nycomed
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast in type 2 diabetes mellitus (T2DM), sponsored by Nycomed. Started Aug 2006; status: completed.
02
Drugs
roflumilast
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-005702-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005702-23.